PT Pharma Metric Labs
Jakarta Pusat, DKI Jakarta, 10520, Indonesia
NCT Number: NCT05753371
The objective of this present study was to investigate whether Glufor® 500 (metformin hydrochloride 500 mg) film-coated tablets manufactured by PT. Pyridam Farma Tbk is bioequivalent to its reference product, Glucophage® 500 mg film-coated tablets manufactured by PT. Merck Tbk, Indonesia under licensed Merck Sante SAS, France.
Looking for future studies?
Notify Me18 year–52 year
All sexes
Interventional
Not applicable
Jakarta Pusat, DKI Jakarta, 10520, Indonesia
Twenty-four subjects were given a single dose of 500 mg Metformin film-coated tablet of either formulation (test or reference) with 240 mL of a 20% glucose solution in water.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
The inclusion criterias were healthy male or female subjects who/with:
Exclusion criteria
s
The subjects' exclusion criterias for the study were:
Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Time frame: 0-24 hours post dose
The ratio between maximum concentration of test drug and reference drug after drug administration
Time frame: 0-24 hours post dose
The ratio between area under curve from 0 to 24 hours of test drug and reference drug
Time frame: 0-24 hours post dose
Maximum plasma concentration (Cmax)
Time frame: 0-24 hours post dose
Area Under Curve from 0 to 24 hours (AUCt)
PT. Pyridam Farma Tbk
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04935606
Drug Use
Long Beach, California, United States
View Trial DetailsNCT05609864
Drug Use
Cannes, Alpes-Maritimes, France
View Trial DetailsNCT05553054
Drug Use
Charleville-Mézières, Ardennes, France
View Trial DetailsNCT04804072
Blood-Borne Infections, Chemically-Induced Disorders
Los Angeles, California, United States
View Trial Details